Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension
Status:
Withdrawn
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of the combination of
ambrisentan and tadalafil in reducing mPAP to below 35mmHg in patients with moderate to
severe Portopulmonary Hypertension (POPH) as a means to candidacy for liver transplantation.